Cover Image
市場調查報告書

全球慢性腎臟病 (CKD) 市場預測 (∼2028年):ACE抑制劑(血管收縮素轉換酵素抑制劑),血管收縮素II受體阻斷劑,鈣通道阻滯劑,β受體阻斷劑,紅血球生成催化劑,利尿劑,院內/零售/線上藥局

Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028: ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis-Stimulating Agents, Diuretic, Hospital/Retail/Online Pharmacies

出版商 Visiongain Ltd 商品編碼 602847
出版日期 內容資訊 英文 171 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球慢性腎臟病 (CKD) 市場預測 (∼2028年):ACE抑制劑(血管收縮素轉換酵素抑制劑),血管收縮素II受體阻斷劑,鈣通道阻滯劑,β受體阻斷劑,紅血球生成催化劑,利尿劑,院內/零售/線上藥局 Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028: ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis-Stimulating Agents, Diuretic, Hospital/Retail/Online Pharmacies
出版日期: 2017年12月05日 內容資訊: 英文 171 Pages
簡介

全球慢性腎臟病 (CKD) 市場2016年達122億美元規模。該市場今後將以3.9%的年複合成長率擴大。

本報告提供全球慢性腎臟病 (CKD) 市場相關調查,市場概要和各市場區隔,各地區趨勢,及加入此市場的主要企業的簡介等彙整資料。

第1章 本報告概要

第2章 簡介

第3章 各類型市場

  • 全球市場預測 (2018∼2028年)
  • 各類藥物市場佔有率
  • 全球ACE抑制劑(血管收縮素轉換酵素抑制劑)市場
  • 全球血管收縮素II受體阻斷劑市場
  • 全球鈣通道阻滯劑市場
  • 全球β受體阻斷劑市場
  • 全球紅血球生成催化劑市場
  • 全球利尿劑市場
  • 其他的市場

第4章 各流通管道市場

  • 各流通管道鹽生預測
    • 院內藥局
    • 零售藥局
    • 線上藥局
    • 其他

第5章 主要國家市場

  • 各地區明細
  • 各地區市場預測

第6章 北美

第7章 歐洲

第8章 亞太地區

第9章 南美

第10章 中東、非洲

第11章 主要企業

  • Sanofi S.A.
  • Pfizer, Inc.
  • Amgen, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Allergan plc
  • AbbVie Inc.
  • Kissei藥品工業株式會社

第12章 結論

附錄

目錄
Product Code: PHA0265

The Global Chronic Kidney Disease (CKD) Drugs market reached $12.2bn in 2016 and is expected to grow at a CAGR of 3.9% in the first half of the forecast period. The market is dominated by calcium channel blockers and ACE inhibitors.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 171-page report you will receive 85 tables and 93 figures - all unavailable elsewhere.

The 171-page report provides clear detailed insight into the Global Chronic Kidney Disease (CKD) Drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Chronic Kidney Disease (CKD) Drugs market forecasts from 2018-2028
  • This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by drug class:
    • ACE inhibitors
    • Angiotensin-II receptor blockers
    • Calcium channel blockers
    • Beta blockers: BREVIBLOC, Bystolic
    • Erythropoiesis-stimulating agents (ESAs)
    • Diuretics
    • Others

This report provides a SWOT Analysis for each drug class.

  • This report provides revenue forecast for these leading drugs:
    • Aceon
    • Lisinopril
    • Losartan
    • AVAPRO
    • Twynsta
    • BREVIBLOC
    • Bystolic
    • Mircera
    • Epoetin Alfa BS
    • Natrilix SR
    • Spironolactone
    • Urief
    • AURYXIA
  • This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by distribution channel:
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
    • Others
  • This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by regional and national market:
    • North America: US and Canada
    • Europe: Germany, the UK, France, Spain, Italy, Rest of Europe
    • Asia-Pacific: Japan, China, India, Rest of Asia-Pacific
    • Latin America: Brazil, Mexico, Rest of Latin America
    • Middle East & Africa: Saudi Arabia, South of Africa, Rest of MEA

Each regional market is further broken down by drug class and distribution channel.

  • This report provides company overview, financial information, product portfolio and recent developments for the leading companies in the Global Chronic Kidney Disease (CKD) Drugs market:
    • Pfizer, Inc.
    • Amgen
    • Roche
    • GlaxoSmithKline (GSK)
    • Allergan
    • AbbVie
    • Kissei Pharmaceutical Co., Ltd.

Buy our report today Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028: ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretic, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Chronic Kidney Disease Drugs Market Overview
  • 1.2. Overview of Findings
  • 1.3. Structure of the Report
  • 1.4. Global Chronic Kidney Disease Drugs Market Segmentation
  • 1.5. Why You Should Read This Report
  • 1.6. How This Report Delivers
  • 1.7. Key Questions Answered by This Analytical Report
  • 1.8. Who is This Report For?
  • 1.9. Methodology
  • 1.10. Associated Visiongain Reports
  • 1.11. About Visiongain

2. Introduction to Chronic Kidney Disease Drugs

  • 2.1. An Introduction to Chronic Kidney Disease Drugs
  • 2.2. ACE Inhibitors
  • 2.3. Angiotensin-II Receptor Blockers
  • 2.4. Calcium Channel Blockers
  • 2.5. Beta Blockers
  • 2.6. Erythropoiesis-stimulating agents (ESAs)
  • 2.7. Diuretics
  • 2.8. Drivers
    • 2.8.1. High Prevalence of Chronic Kidney Disease (CKD) Worldwide
    • 2.8.2. Rise in Incidence of Cardiovascular Disorders and Diabetes
  • 2.9. Restraints
    • 2.9.1. Competition from Biosimilars Due to Patent Loss

3. Global Chronic Kidney Disease Drugs Market by Product Type 2018-2028

  • 3.1. Global Chronic Kidney Disease Drugs Market Forecast 2018-2028
  • 3.2. Changing Market Shares by Drug Class 2018-2028
  • 3.3. Global ACE Inhibitors Market: Sales Forecast 2018-2028
    • 3.3.1. Aceon (Abbott Laboratories)
    • 3.3.2. Lisinopril (GlaxoSmithKline plc.)
    • 3.3.3. SWOT Analysis of the ACE Inhibitors Market, 2018-2028
      • 3.3.3.1. Strength
        • 3.3.3.1.1. Advantages of ACE Inhibitors drugs
      • 3.3.3.2. Weakness
        • 3.3.3.2.1. Side effect of ACE Inhibitors
      • 3.3.3.3. Opportunity
        • 3.3.3.3.1. Increasing prevalence of cardiovascular disease
      • 3.3.3.4. Threat
        • 3.3.3.4.1. Competitive and Fragmented market
  • 3.4. Global Angiotensin-II Receptor Blockers Market: Sales Forecast 2018-2028
    • 3.4.1. Losartan (Morepen Laboratories Ltd.)
    • 3.4.2. AVAPRO (Sanofi S.A.)
    • 3.4.3. SWOT Analysis of the Angiotensin-II Receptor Blockers Market, 2018-2028
      • 3.4.3.1. Strength
        • 3.4.3.1.1. Blood pressure lowering efficacy in patients with hypertension
      • 3.4.3.2. Weakness
        • 3.3.3.2.1. Side effects during pregnancy
      • 3.4.3.3. Opportunity
        • 3.4.3.3.1. Increasing prevalence of Diabetic Kidney Disease
      • 3.4.3.4. Threat
        • 3.4.3.4.1. Fewer interactions with other drugs
  • 3.5. Global Calcium Channel Blockers Market: Sales Forecast 2018-2028
    • 3.5.1. Norvasc (Pfizer Inc.)
    • 3.5.2. Twynsta (Boehringer Ingelheim Pharmaceuticals, Inc.)
    • 3.5.3. SWOT Analysis of the Calcium Channel Blockers Market, 2018-2028
      • 3.5.3.1. Strength
        • 3.5.3.1.1. Favourable Reimbursement Scenario
      • 3.5.3.2. Weakness
        • 3.5.3.2.1. Side effect of Calcium Channel Blockers
      • 3.5.3.3. Opportunity
        • 3.5.3.3.1. Rising prevalence of hypertension across the globe
      • 3.5.3.4. Threat
        • 3.5.3.4.1. Availability of cost effective biosimilars
  • 3.6. Global Beta Blockers Market: Sales Forecast 2018-2028
    • 3.6.1. BREVIBLOC (Baxter International Inc.)
    • 3.6.2. Bystolic (ALLERGAN)
    • 3.6.3. SWOT Analysis of the Beta Blockers Market, 2018-2028
      • 3.6.3.1. Strength
        • 3.6.3.1.1. Advantages of Beta Blockers
      • 3.6.3.2. Weakness
        • 3.6.3.2.1. Can't be used by Diabetes Patients
      • 3.6.3.3. Opportunity
        • 3.6.3.3.1. Increasing prevalence of heart failure
      • 3.6.3.4. Threat
        • 3.6.3.4.1. Availability of cost effective biosimilars
  • 3.7. Global Erythropoiesis-stimulating agents (ESAs) Market: Sales Forecast 2018-2028
    • 3.7.1. Mircera (F. Hoffmann-La Roche AG)
    • 3.7.2. Epoetin Alfa BS (Japan Chemical Research Pharmaceuticals Co., Ltd.)
    • 3.7.3. SWOT Analysis of the Erythropoiesis-stimulating agents (ESAs) Market, 2018-2028
      • 3.7.3.1. Strength
        • 3.7.3.1.1. Mircera launched in the U.S.
      • 3.7.3.2. Weakness
        • 3.7.3.2.1. Mircera is not a preferred brand of the Payers
      • 3.7.3.3. Opportunity
        • 3.7.3.3.1. Increased incidences of kidney failures
      • 3.7.3.4. Threat
        • 3.7.3.4.1. Availability of cost effective biosimilars
  • 3.8. Global Diuretics Market: Sales Forecast 2018-2028
    • 3.8.1. Natrilix SR (Serdia Pharmaceuticals Pvt. Ltd.)
    • 3.8.2. Spironolactone (Pfizer, Inc.)
    • 3.8.3. SWOT Analysis of the Diuretics Market, 2018-2028
      • 3.8.3.1. Strength
        • 3.8.3.1.1. Reduces Risk of Congestive heart Failure Hospitalization
      • 3.8.3.2. Weakness
        • 3.8.3.2.1. Can Cause Heart Rhythm Problems
      • 3.8.3.3. Opportunity
        • 3.8.3.3.1. Increasing prevalence of Congestive Heart Failure
      • 3.8.3.4. Threat
        • 3.8.3.4.1. Generic Competition
  • 3.9. Global Others Market: Sales Forecast 2018-2028
    • 3.9.1. Urief (Kissei Pharmaceutical Co., Ltd., Eisai Co., Ltd)
    • 3.9.2. AURYXIA (Keryx Biopharmaceuticals, Inc.)

4. Global Chronic Kidney Disease Drugs Market by Distribution Channel 2018-2028

  • 4.1. Global Chronic Kidney Disease Drugs Market Forecast by Distribution Channel 2018-2028
    • 4.1.1. Hospital Pharmacies
    • 4.1.2. Retail Pharmacies
    • 4.1.3. Online Pharmacies
    • 4.1.4. Others (Clinics, Supermarket Drug Stores, etc.)

5. Leading National Markets 2018-2028

  • 5.1. Geographical Breakdown of the World Chronic Kidney Disease Drugs Market
  • 5.2. Chronic Kidney Disease Drugs Market: Regional Market Forecast 2018-2028
    • 5.2.1. How Will Regional Market Shares Change to 2028?

6. North America Chronic Kidney Disease Drugs Market 2018-2028

  • 6.1. U.S. Chronic Kidney Disease Drugs Market: Trends and Developments
  • 6.2. Canada Chronic Kidney Disease Drugs Market: Trends and Developments

7. Europe Chronic Kidney Disease Drugs Market 2018-2028

  • 7.1. Germany Chronic Kidney Disease Drugs Market Forecast 2018-2028
  • 7.2. France Chronic Kidney Disease Drugs Market Forecast 2018-2028
  • 7.3. U.K. Chronic Kidney Disease Drugs Market Forecast 2018-2028
  • 7.4. Italy Chronic Kidney Disease Drugs Market Forecast 2018-2028
  • 7.5. Spain Chronic Kidney Disease Drugs Market Forecast 2018-2028
  • 7.6. Rest of Europe Chronic Kidney Disease Drugs Market Forecast 2018-2028

8. Asia-Pacific Chronic Kidney Disease Drugs Market 2018-2028

  • 8.1. China Chronic Kidney Disease Drugs Market: Trends and Developments
  • 8.2. Japan Chronic Kidney Disease Drugs Market: Trends and Developments
  • 8.3. India Chronic Kidney Disease Drugs Market: Trends and Developments
  • 8.4. Rest of Asia-Pacific Chronic Kidney Disease Drugs Market: Trends and Developments

9. Latin America Chronic Kidney Disease Drugs Market 2018-2028

  • 9.1. Brazil Chronic Kidney Disease Drugs Market: Trends and Developments
  • 9.2. Mexico Chronic Kidney Disease Drugs Market: Trends and Developments
  • 9.3. Rest of Latin America Chronic Kidney Disease Drugs Market: Trends and Developments

10. Middle East & Africa Chronic Kidney Disease Drugs Market 2018-2028

  • 10.1. Saudi Arabia Chronic Kidney Disease Drugs Market Forecast 2018-2028
  • 10.2. South Africa Chronic Kidney Disease Drugs Market Forecast 2018-2028
  • 10.3. Rest of Middle East & Africa Chronic Kidney Disease Drugs Market Forecast 2018-2028

11. Leading Companies in the Chronic Kidney Disease Drugs

  • 11.1. Sanofi S.A.
    • 11.1.1. Sanofi S.A.: Chronic Kidney Disease Drugs Portfolio
    • 11.1.2. Sanofi S.A.: Financial Overview
    • 11.1.3. Sanofi S.A.: Recent Developments
  • 11.2. Pfizer, Inc.
    • 11.2.1. Pfizer, Inc.: Chronic Kidney Disease Drugs Portfolio
    • 11.2.2. Pfizer, Inc.: Financial Overview
    • 11.2.3. Pfizer, Inc.: Recent Developments
  • 11.3. Amgen, Inc.
    • 11.3.1. Amgen, Inc.: Chronic Kidney Disease Drugs Portfolio
    • 11.3.2. Financial Overview
    • 11.3.3. Recent Transactions Summary
  • 11.4. F. Hoffmann-La Roche AG
    • 11.4.1. Roche: Chronic Kidney Disease Drugs Portfolio
    • 11.4.2. Roche: Financial Overview
    • 11.4.3. Recent Transactions Summary
  • 11.5. GlaxoSmithKline plc
    • 11.5.1. GlaxoSmithKline plc: Chronic Kidney Disease Drugs Portfolio
    • 11.5.2. GlaxoSmithKline plc: Financial Overview
    • 11.5.3. GlaxoSmithKline plc: Recent Transactions Summary
  • 11.6. Allergan plc
    • 11.6.1. Allergan plc: Chronic Kidney Disease Drugs Portfolio
    • 11.6.2. Allergan plc: Financial Overview
    • 11.6.3. Allergan plc: Recent Transactions Summary
  • 11.7. AbbVie Inc.
    • 11.7.1. AbbVie Inc.: Chronic Kidney Disease Drugs Portfolio
    • 11.7.2. AbbVie Inc.: Financial Overview
    • 11.7.3. AbbVie Inc.: Recent Transactions Summary
  • 11.8. Kissei Pharmaceutical Co., Ltd
    • 11.8.1. Kissei Pharmaceutical Co., Ltd.: Chronic Kidney Disease Drugs Portfolio
    • 11.8.2. Kissei Pharmaceutical Co., Ltd.: Financial Overview
    • 11.8.3. Kissei Pharmaceutical Co., Ltd.: Recent Transactions Summary

12. Conclusions

  • 12.1. The World Chronic Kidney Disease Drugs Market in 2016 and 2017
    • 12.1.1. Current Leading Chronic Kidney Disease Drugs Segments
    • 12.1.2. Leading Regional Markets
  • 12.2. World Chronic Kidney Disease Drugs Market Forecast 2017-2027
  • 12.3. The Future of the Military Medical & Humanitarian Trauma Care Market?

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 3.1: Global Chronic Kidney Disease Drugs Market by Drugs Class: Revenue($m) and Market Share(%), 2016
  • Table 3.2: Global Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.3: Global ACE Inhibitors Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.4: Global Aceon Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.5: Global Lisinopril Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.6: SWOT Analysis of the ACE Inhibitors Market, 2018-2028
  • Table 3.7: Global Angiotensin-II Receptor Blockers Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.8: Global Losartan Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.9: Global AVAPRO Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.10: SWOT Analysis of the Angiotensin-II Receptor Blockers Market, 2018-2028
  • Table 3.11: Global Calcium Channel Blockers Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.12: Global Norvasc Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.13: Global Twynsta Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.14: SWOT Analysis of the Calcium Channel Blockers Market, 2018-2028
  • Table 3.15: Global Beta Blockers Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.16: Global BREVIBLOC Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.17: Global Bystolic Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.18: SWOT Analysis of the Beta Blockers Market, 2018-2028
  • Table 3.19: Global Erythropoiesis-stimulating agents(ESAs) Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.20: Global Mircera Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.21: Global Epoetin Alfa BS Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.22: SWOT Analysis of the Erythropoiesis-stimulating agents(ESAs) Market, 2018-2028
  • Table 3.23: Global Diuretics Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.24: Global Natrilix SR Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.25: Global Spironolactone Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.26: SWOT Analysis of the Diuretics Market, 2018-2028
  • Table 3.27: Global Others Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.28: Global Urief Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 3.29: Global AURYXIA Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 4.1: Global Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 4.2: Global Hospital Pharmacies Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 4.3: Global Retail Pharmacies Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 4.4: Global Online Pharmacies Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 4.5: Global Others Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 5.1: Global Chronic Kidney Disease Drugs Market by Region: Revenue($m), 2016 and 2017
  • Table 5.2: Global Chronic Kidney Disease Drugs Market Forecast, by Region: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 6.1: North America Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 6.2: North America Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 6.3: North America Chronic Kidney Disease Drugs Market Forecast, by End User: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 6.4: U.S. Chronic Kidney Disease Drugs Market Forecast, by End User: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 6.5: Canada Chronic Kidney Disease Drugs Market Forecast, by End User: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 7.1: Europe Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 7.2: Europe Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 7.3: Europe Chronic Kidney Disease Drugs Market Forecast, by Country: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 7.4: Germany Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 7.5: France Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 7.6: U.K. Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 7.7: Italy Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 7.8: Spain Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 7.9: Rest of Europe Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 8.1: Asia-Pacific Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 8.2: Asia-Pacific Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 8.3: Asia-Pacific Chronic Kidney Disease Drugs Market Forecast, By Country: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 8.4: China Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 8.5: Japan Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 8.6: India Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 8.7: Rest of Asia-Pacific Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 9.1: Latin America Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 9.2: Latin America Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 9.3: Latin America Chronic Kidney Disease Drugs Market Forecast, by Country: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 9.4: Brazil Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 9.5: Mexico Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 9.6: Rest of Latin America Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 10.1: Middle East & Africa Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 10.2: Middle East & Africa Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 10.3: Middle East & Africa(MEA) Chronic Kidney Disease Drugs Market Forecast, by Country: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 10.4: Saudi Arabia Chronic Kidney Disease Drugs Market Forecast, by Country: Revenues($m), AGR(%), CAGR(%), 2016-2028
  • Table 10.5: South Africa Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 10.6: Rest of MEA Chronic Kidney Disease Drugs Market Forecast, 2016-2028($m, AGR %, CAGR %)
  • Table 11.1: Sanofi S.A.: Overview, 2017
  • Table 11.2: Sanofi S.A.: Revenue($m), AGR(%), 2012-2016
  • Table 11.3: Pfizer, Inc.: Overview, 2017
  • Table 11.4: Pfizer, Inc.: Revenue($m), AGR(%), 2012-2016
  • Table 11.5: Amgen, Inc. Corporation: Overview, 2017
  • Table 11.6: Amgen, Inc.: Revenue($m), AGR(%), 2012-2016
  • Table 11.7: Roche: Overview, 2017
  • Table 11.8: Roche: Revenue($m), AGR(%), 2012-2016
  • Table 11.9: GlaxoSmithKline plc: Overview, 2017
  • Table 11.10: GlaxoSmithKline plc: Revenue($m), AGR(%), 2012-2016
  • Table 11.11: Allergan plc: Overview, 2017
  • Table 11.12: Allergan plc: Revenue($m), AGR(%), 2012-2016
  • Table 11.13: AbbVie Inc.: Overview, 2017
  • Table 11.14: AbbVie Inc.: Revenue($m), AGR(%), 2012-2016
  • Table 11.15: Kissei Pharmaceutical Co., Ltd: Overview, 2017
  • Table 11.16: Kissei Pharmaceutical Co., Ltd: Revenue($m), AGR(%), 2013-2017

List of Figure

  • Figure 1.1: Global Chronic kidney diseases Drugs Market Segmentation Overview
  • Figure 3.1: Global Chronic Kidney Disease Drugs Market by Drugs Class: Market Share(%), 2016
  • Figure 3.2: Global Chronic Kidney Disease Drugs Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.3: Global Chronic Kidney Disease Drugs Market by Drugs Class: Market Share(%), 2016
  • Figure 3.4: Global Chronic Kidney Disease Drugs Market by Drugs Class: Market Share(%), 2022
  • Figure 3.5: Global Chronic Kidney Disease Drugs Market by Drugs Class: Market Share(%), 2028
  • Figure 3.6: Global ACE Inhibitors Segment Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.7: Global Aceon Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.8: Global Lisinopril Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.9: Global Angiotensin-II Receptor Blockers Segment Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.10: Global Losartan Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.11: Global AVAPRO Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.12: Global Calcium Channel Blockers Segment Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.13: Global Norvasc Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.14: Global Twynsta Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.15: Global Beta Blockers Segment Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.16: Global BREVIBLOC Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.17: Global Bystolic Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.18: Global Erythropoiesis-stimulating agents(ESAs) Segment Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.19: Global Mircera Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.20: Global Epoetin Alfa BS Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.21: Global Diuretics Segment Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.22: Global Natrilix SR Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.23: Global Spironolactone Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.24: Global Others Segment Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.25: Global Urief Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 3.26: Global AURYXIA Market Forecast: Revenue($m), AGR(%), 2016-2028
  • Figure 4.1: Global Chronic kidney disease Drugs Market by Distribution Channel: Market Share(%), 2016
  • Figure 4.2: Global Hospital Pharmacies Segment Forecast: Revenue($m), AGR(%), 2018-2028
  • Figure 4.3: Global Retail Pharmacies Segment Forecast: Revenue($m), AGR(%), 2018-2028
  • Figure 4.4: Global Online Pharmacies Segment Forecast: Revenue($m), AGR(%), 2018-2028
  • Figure 4.5: Global Others Segment Forecast: Revenue($m), AGR(%), 2018-2028
  • Figure 5.1: Global Chronic Kidney Disease Drugs Market: Revenues($m) by Region, 2016
  • Figure 5.2: Global Chronic Kidney Disease Drugs Market: Revenues($m) by Region, 2017
  • Figure 5.3: Global Chronic Kidney Disease Drugs Market Forecast by Regional Market: Revenue($m), 2016-2028
  • Figure 5.4: Global Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2016
  • Figure 5.5: Global Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2022
  • Figure 5.6: Global Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2028
  • Figure 6.1: North America Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 6.2: North America Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2016
  • Figure 6.3: North America Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2022
  • Figure 6.4: North America Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2028
  • Figure 6.5: U.S. Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 6.6: Canada Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 7.1: Europe Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 7.2: Europe Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2016
  • Figure 7.3: Europe Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2022
  • Figure 7.4: Europe Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2028
  • Figure 7.5: Germany Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 7.6: France Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 7.7: U.K. Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 7.8: Italy Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 7.9: Spain Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 7.10: Rest of Europe Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 8.1: Asia-Pacific Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 8.2: Asia-Pacific Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2016
  • Figure 8.3: Asia-Pacific Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2022
  • Figure 8.4: Asia-Pacific Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2028
  • Figure 8.5: China Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 8.6: Japan Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 8.7: India Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 8.8: Rest of Asia-Pacific Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 9.1: Latin America Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 9.2: Latin America Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2016
  • Figure 9.3: Latin America Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2022
  • Figure 9.4: Latin America Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2028
  • Figure 9.5: Brazil Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 9.6: Mexico Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 9.7: Rest of Latin America Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 10.1: Middle East & Africa Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 10.2: Middle East & Africa Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2016
  • Figure 10.3: Middle East & Africa Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2022
  • Figure 10.4: Middle East & Africa Chronic Kidney Disease Drugs Market: Market Shares(%) by Regional Market, 2028
  • Figure 10.5: Saudi Arabia Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 10.6: South Africa Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 10.7: Rest of MEA Chronic Kidney Disease Drugs Market Forecast: Revenues($m), AGR(%), 2016-2028
  • Figure 11.1: Sanofi S.A.: Revenue($m), AGR(%), 2012-2016
  • Figure 11.2: Sanofi S.A.: Revenue, by Region, Share(%), 2016
  • Figure 11.3: Pfizer, Inc.: Revenue($m), AGR(%), 2012-2016
  • Figure 11.4: Pfizer, Inc.: National Revenue Share(%), 2016
  • Figure 11.5: Amgen, Inc.: Revenue($m), AGR(%), 2012-2016
  • Figure 11.6: Roche: Revenue($m), AGR(%), 2012-2016
  • Figure 11.7: Roche: Business Segment Revenue Share(%), 2016
  • Figure 11.8: GlaxoSmithKline plc: Revenue($m), AGR(%), 2012-2016
  • Figure 11.9: GlaxoSmithKline plc: Business Segment Revenue Share(%), 2016
  • Figure 11.10: Allergan plc: Revenue($m), AGR(%), 2012-2016
  • Figure 11.11: Allergan plc: Business Segment Revenue Share(%), 2016
  • Figure 11.12: AbbVie Inc.: Revenue($m), AGR(%), 2012-2016
  • Figure 11.13: AbbVie Inc.: Geography Revenue Share(%), 2016
  • Figure 11.14: Kissei Pharmaceutical Co., Ltd: Revenue($m), AGR(%), 2013-2017
  • Figure 11.15: Kissei Pharmaceutical Co., Ltd.: Business Segment Revenue Share(%), 2016
  • Figure 12.1: Global Chronic Kidney Disease Drugs Market by Product Type: Market Share(%), 2016
  • Figure 12.2: Chronic Kidney Disease Drugs Market, by Region Share(%), 2016, 2022, 2028

Companies Listed

  • Abbott Laboratories
  • AbbVie, Inc.
  • Allergan plc
  • Amgen, Inc.
  • AstraZeneca Pharmaceuticals LP
  • Bausch & Lomb Incorporated
  • Baxter International Inc.
  • Bayer
  • Boehringer Ingelheim GmbH
  • Eisai Co., Ltd
  • Emory Healthcare
  • F. Hoffmann-La Roche Ltd
  • Fresenius
  • Galenica
  • GlaxoSmithKline plc
  • Hospira
  • Instituto Terapeutico Delta Ltd
  • Japan Chemical Research Pharmaceuticals Co., Ltd.
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Lupin Laboratories Ltd.
  • Manus Aktteva Biopharma LLP.
  • Morepen Laboratories Ltd.
  • Novartis International AG
  • ObsEva
  • Pfizer, Inc.
  • Sanofi S.A.
  • Sanofi-aventis U.S. LLC
  • Serdia Pharmaceuticals Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • Validus Pharmaceuticals, Inc.
  • Vifor Fresenius Medical Care Renal Pharma
  • Zydus Cadila

Other Organizations Mentioned in the Report:

  • American Diabetes Association
  • American Kidney Fund
  • Asian Diabetes Prevention Initiative
  • Cancer Research U.K.
  • Centers for Disease Control and Prevention
  • Diabetes.co.uk
  • European Heart Network
  • Health Canada
  • Indian Heart Association
  • International Diabetes Federation
  • International Diabetes Foundation
  • National Center for Biotechnology Information
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Kidney Foundation
  • National Organization of Rare Disorders
  • Servicio Sanitario Nazionale
  • Surgical Reconstruction and Microbiology Research Centre
  • The Kidney Foundation of Canada
  • U.S. Department of Commerce
  • U.S. Food and Drug Administration (FDA)
  • U.S. National Institutes of Health
  • United Nations
  • University of San Jose-Recoletos
  • World Economic Forum
  • World Health Organization
Back to Top